The Bio Report

The ability to identify diseases at their earliest stages through the detection of minute levels of biomarkers offers the potential to make interventions before the outward physical manifestations of illnesses can bloom and long-term damage can occur. Quanterix is developing a platform of ultra-sensitive biomarker tests to give researchers greater insight into the transition from health to disease and the ability to detect diseases at an earlier point in their development. We spoke to Kevin Hrusovsky, chairman, president, and CEO of Quanterix, about the company’s ability to detect minute amounts of biomarkers, the implications this has for drug development and diagnostics, and how this can help drive a future of precision health.